Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Faith E. Davies(Institute of Cancer Research), Kenneth C. Anderson(Novartis (Switzerland)), Yu‐Tzu Tai(Harvard University), Suzanne Lentzsch(UPMC Hillman Cancer Center), Paul G. Richardson(Dana-Farber Cancer Institute), Noopur Raje(Dana-Farber Cancer Institute), Steven P. Treon(Harvard University), Teru Hideshima(Dana-Farber Cancer Institute), Gareth J. Morgan(NYU Langone Health), Deepak Gupta(University of Leeds), Gloria Young(University of Leeds), Robert Schlossman(University of Leeds), Boris K. Lin(University of Leeds), George W. Muller(University of Leeds), Dharminder Chauhan(University of Leeds), David Stirling(University of Leeds), Klaus Podar(Dana-Farber Cancer Institute)
Blood
July 1, 2001
10.1182/blood.v98.1.210
Cited by 905

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k